1. Epigenetics
  2. PKC
  3. Delcasertib hydrochloride

Delcasertib hydrochloride (Synonyms: KAI-9803 hydrochloride; BMS-875944 hydrochloride)

Cat. No.: HY-106262B
Handling Instructions

Delcasertib hydrochloride (KAI-9803 hydrochloride) is a potent and selective δ-protein kinase C (δPKC) inhibitor.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

Delcasertib hydrochloride Chemical Structure

Delcasertib hydrochloride Chemical Structure

Size Price Stock Quantity
5 mg USD 450 In-stock
Estimated Time of Arrival: December 31
10 mg USD 750 In-stock
Estimated Time of Arrival: December 31
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Delcasertib hydrochloride:

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review


Delcasertib hydrochloride (KAI-9803 hydrochloride) is a potent and selective δ-protein kinase C (δPKC) inhibitor[1][2].

IC50 & Target[1]



In Vitro

Delcasertib (KAI-9803) is composed of a selective δ-protein kinase C (δPKC) inhibitor peptide derived from the δV1-1 portion of δPKC (termed “cargo peptide”), conjugated reversibly to the cell-penetrating peptide 11-amino acid, arginine-rich sequence of the HIV type 1 transactivator protein (TAT47–57; termed “carrier peptide”) via a disulfide bond[1].

In Vivo

Delcasertib (KAI-9803, a single intraperitoneal injection) in mice results in the selective inhibition of PKC translocation in the liver, kidney, lung, heart, and brain[1].
Delcasertib (KAI-9803) administration at the end of ischemia has been found to reduce cardiac damage caused by ischemia-reperfusion in a rat model of acute myocardial infarction[1].
Delcasertib (KAI-9803) has been studied for the prevention of reperfusion injury in patients undergoing angioplasty after acute myocardial infarction[2].

Animal Model: Six-week-old male Crl:CD(SD) rats[1]
Dosage: 1 mg/kg (Pharmacokinetic Analysis).
Administration: Via the femoral vein.
Result: The distribution to tissues such as the liver, kidney, and heart is facilitated by the reversible conjugation to TAT47-57.
Molecular Weight




Sequence Shortening

Sequence 1:CYGRKKRRQRRR;Sequence 1':CSFNSYELGSL (Disulfide bridge:Cys1-Cys1’)


Room temperature in continental US; may vary elsewhere.


Please store the product under the recommended conditions in the Certificate of Analysis.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2


DelcasertibKAI-9803BMS-875944KAI9803KAI 9803BMS875944BMS 875944PKCProtein kinase CacutemyocardialinfarctionischemiaInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name



Applicant Name *


Email address *

Phone number *


Organization name *

Department *


Requested quantity *

Country or Region *



Bulk Inquiry

Inquiry Information

Product Name:
Delcasertib hydrochloride
Cat. No.:
MCE Japan Authorized Agent: